Genetics help solve eye cancer mystery

Article

It is now possible, for the first time, to biopsy tissue from a living eye in order to determine which tumours possess high metastatic risk, according to a report in the November 2006 issue of Ophthalmology.

It is now possible, for the first time, to biopsy tissue from a living eye in order to determine which tumours possess high metastatic risk, according to a report in the November 2006 issue of Ophthalmology.

Researchers from the University of California Los Angeles, Jules Stein Eye Institute, USA, have pioneered a technique that allows them to identify which tumours are the most aggressive and are likely to spread. Ocular melanoma attacks the pigment cells in the retina and previous studies discovered that subjects who are missing one copy of chromosome 3 in their tumour tissue are more likely to have highly aggressive cancers.

The UCLA researchers, using this genetic marker, studied a group of nine patients, newly diagnosed with ocular melanoma. Each patient underwent surgery to implant a small disc designed to shrink the tumour and during surgery surgeons used an ultra-fine needle to collect cells from the tumour and send them to the laboratory for culture. After growing the cells a geneticist analysed them to determine whether they were missing the essential gene. Of the nine patients, four were identified as being high risk and five as being low risk.

The authors believe that this new technique will not only provide a greater medical understanding of each case but will also go some way to help alleviate the patients psychological trauma of not knowing what kind of cancer they have and whether it is likely to be life-threatening or not.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.